Total Results: 7185
In its investigation of why health care costs are so high, ProPublica reports on the perfectly good stuff hospitals throw away.
In other news on pharmaceutical costs, Sen. Chuck Grassley (R-Iowa) questions Kaleo about the $4,500 price tag of its EpiPen alternative and some payers are denying coverage of pricey hepatitis C treatments, despite more discounts.
Proposed state legislation would ban drugmakers from issuing coupons to lower patients’ copayments if a cheaper, FDA-approved medication is available.
Bloomberg reports on the company’s plans to expand its market and set up its own distribution network. In other health industry news, Walgreens’ CEO talks to analysts about plans for the merger with Rite Aid, a judge rules against Regeneron Pharmaceuticals and Sanofi on a patent dispute and traders are optimistic about biotech sector.
Federal spending for Medicare Part D catastrophic coverage spiked to $33 billion in 2015, a government report shows.
In other marketplace news, closing arguments in the Anthem-Cigna merger antitrust trial are delivered and a filing alleges that Alexion managers encouraged improper sales practices by employees.
The Vermont senator and former presidential candidate is championing the measure to curb high drug prices, which recent polls suggest is supported by more than half of Californians.
Surprise medical bill protections for consumers and new painkiller prescribing requirements for doctors are among measures signed by Gov. Jerry Brown.
Commentators analyze how the election could affect health care and policy in California.
One solution to the EpiPen controversy, some advocates say, is classifying it as preventive care so consumers wouldn’t have to pay anything for the life-saving drug. But while the suggestions seems to favor consumers, a New York Times report finds Mylan is pulling the strings.